β-Amyloid (22-40) is a peptide fragment of β-Amyloid.
β-Amyloid 22-40 is a synthetic peptide fragment derived from the larger amyloid beta (Aβ) protein sequence, which is widely recognized for its central role in neurodegenerative disease research, particularly in studies of Alzheimer's disease and related protein aggregation disorders. Comprising amino acid residues 22 to 40 of the full-length amyloid beta peptide, this segment is notable for its unique biophysical and aggregation properties, making it a valuable tool for dissecting the mechanisms of amyloid formation, toxicity, and structure-function relationships in vitro. Researchers utilize β-Amyloid 22-40 to model specific aspects of amyloidogenic processes and to explore the molecular determinants of peptide aggregation, interactions with cellular components, and the modulation of neurotoxic pathways.
Aggregation studies: As a defined peptide fragment, β-Amyloid 22-40 serves as a model system for investigating the kinetics and structural pathways of amyloid fibril formation. Its sequence encompasses regions critical for self-association, allowing scientists to examine nucleation, elongation, and the influence of environmental conditions on aggregation propensity. By monitoring fibril formation using biophysical techniques such as Thioflavin T fluorescence, circular dichroism spectroscopy, or electron microscopy, researchers can elucidate the molecular events underlying amyloidogenesis and compare the aggregation behavior of this fragment to other Aβ variants or full-length peptides.
Neurotoxicity assays: The peptide is frequently employed in cell-based and biochemical assays designed to assess the cytotoxic effects of amyloid aggregates. By exposing neuronal or glial cell cultures to β-Amyloid 22-40, investigators can evaluate the impact of oligomeric and fibrillar species on cell viability, oxidative stress, and apoptotic signaling pathways. These studies provide critical insights into the mechanisms by which specific amyloid fragments contribute to neurodegeneration, supporting the development of targeted strategies to mitigate peptide-induced toxicity in model systems.
Structure-activity relationship analysis: β-Amyloid 22-40 is instrumental in mapping the structural determinants of amyloid function and dysfunction. Through mutagenesis, chemical modification, or truncation studies, researchers can dissect the contributions of specific amino acid residues within the 22-40 region to aggregation kinetics, secondary structure, and biological effects. Such analyses advance understanding of the sequence-structure relationships that govern amyloid behavior and inform the rational design of peptide analogs or inhibitors with modified biophysical properties.
Screening of aggregation modulators: The defined nature of this peptide fragment makes it a robust platform for high-throughput screening of small molecules, peptides, or antibodies that modulate amyloid aggregation. By assessing the ability of candidate compounds to inhibit or alter the assembly of β-Amyloid 22-40 into oligomers or fibrils, researchers can identify potential leads for further development as molecular probes or as tools to dissect aggregation pathways. These screening efforts contribute to the broader field of amyloid research by providing mechanistic insights and supporting the discovery of aggregation-modifying agents.
Analytical method development: β-Amyloid 22-40 is also utilized in the calibration and validation of analytical techniques for detecting and quantifying amyloid species. Its well-defined sequence and aggregation profile enable its use as a reference standard in mass spectrometry, chromatography, or immunoassays, facilitating the development of sensitive and specific methods for amyloid detection in complex biological samples. This application is particularly valuable for ensuring assay reproducibility and for benchmarking the analytical performance of new detection platforms in amyloid research.
1. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment
4. TMEM16F and dynamins control expansive plasma membrane reservoirs
5. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More